Smith & Nephew plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Deepak S Nath
- Full Time Employees
- 18,362
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Building 5 Croxley Park Hatters Lane Watford HRT United Kingdom WD18 8YE
- IPO Date
- Aug 13, 1951
- Website
- smith-nephew.com
- Similar Companies
- Business
- Smith & Nephew plc develops, manufactures, markets and sells medical devices and services focused on the repair, regeneration and replacement of soft and hard tissue. The company operates through three global business units: Orthopaedics, offering hip, knee and shoulder implants for joint replacement procedures, robotics-assisted enabling technologies such as the CORI Surgical System, trauma and extremities products for fracture stabilization and bone deformity correction; Sports Medicine & ENT, providing advanced arthroscopy products, instruments for soft tissue repair or removal, cartilage regeneration technologies like Agili-C and ear, nose and throat solutions; and Advanced Wound Management, delivering negative pressure wound therapy systems such as PICO, antimicrobial dressings, biological products and skin substitutes to address complex clinical needs and reduce wound-related consequences. Founded in 1856 and headquartered in Watford, Hertfordshire, UK, Smith & Nephew employs approximately 18,000 people and conducts operations in more than 100 countries, serving hospitals, clinics and healthcare professionals worldwide with annual sales of $5.8 billion in 2024. Recent developments include a multi-year extension of its partnership with UFC as the Preferred Sports Medicine Technology Partner announced in October 2025, building on the 2024 agreement to promote health and safety advancements in combat sports; revised plans in 2024 for a new 23-acre research, development and manufacturing site in Melton, UK, under an £80 million project while retaining certain Hull facilities amid cost increases; completion of the CartiHeal acquisition in early 2024 to bolster knee cartilage regeneration capabilities; and implementation of a 12-Point Plan driving revenue growth as evidenced by third-quarter 2025 results.
Company News
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo.
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
Smith & Nephew SNATS (NYSE:SNN) Reaches New 52-Week Low – Time to Sell?
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds
Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued
Smith & Nephew SNATS (NYSE:SNN) Hits New 52-Week Low Following Analyst Downgrade
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism
Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit
UBS cuts Smith & Nephew target on competitive threats to three franchises
BlackRock Inc. Invests $505.32 Million in Smith & Nephew SNATS, Inc. $SNN
SNN Advances Surgical Robotics Through Imperial College Partnership
Smith & Nephew shares slip on CFO's departure